Antibiotic resistance: location, location, location.

Antibiotic resistance surveys are published widely, citing percentage resistance rates, sometimes for vast transcontinental regions. Such data seem straightforward, but when one drills deeper, great complexity emerges. Rates for methicillin resistance among Staphylococcus aureus from bacteraemias vary from <1% to 50% among European countries, and vary greatly among both hospitals and hospital units. Methicillin-resistant S. aureus (MRSA) resistance rates are typically higher for tertiary-care hospitals and intensive care units than in general hospitals and wards, and lowest in single specialist centres. The likelihood of resistance also varies according to patient characteristics: those patients from nursing homes and with underlying disease, recent antibiotic treatment and hospitalisation are more likely to harbour resistant pathogens. Percentage rates themselves also may be misleading; they may be high only because the denominator is small or inaccurate; i.e., resistance may be common but the pathogen rare. Measures of disease burden-cases per 1000 bed-days or per 10(5) individuals-overcome this deficiency but are harder to collect, influenced by case mix, and associated with other problems: how to count part days or infections acquired elsewhere; most important, are all cases captured? National or international resistance statistics may illustrate trends and provide benchmarks, but for patient management, good local data are essential. Which units are most affected? Are the resistant infections locally acquired or imported with transferred patients? Are the resistant isolates clonal, indicating cross-infection, or diverse, indicating repeated selection or reflecting antibiotic policy? Unless these aspects of infection are considered, interventions to reduce resistance may be misdirected.

[1]  G. Duckworth,et al.  Surveillance and epidemiology of MRSA bacteraemia in the UK. , 2005, The Journal of antimicrobial chemotherapy.

[2]  J. Jordens Characterisation of non-capsulate Haemophilus influenzae by repetitive extragenic palindromic (REP)-PCR. , 1998, Journal of medical microbiology.

[3]  O. Stine,et al.  Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. , 2006, The American journal of medicine.

[4]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.

[5]  R. Masterton,et al.  Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). , 2006, International journal of antimicrobial agents.

[6]  P. Hsueh,et al.  In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, International journal of antimicrobial agents.

[7]  P. Donnan,et al.  Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data , 2004, BMJ : British Medical Journal.

[8]  Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States , 2006 .

[9]  M. Gardam,et al.  Complete Nucleotide Sequence of a 92-Kilobase Plasmid Harboring the CTX-M-15 Extended-Spectrum Beta-Lactamase Involved in an Outbreak in Long-Term-Care Facilities in Toronto, Canada , 2004, Antimicrobial Agents and Chemotherapy.

[10]  Ronald N. Jones,et al.  Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. , 2004, Diagnostic microbiology and infectious disease.

[11]  F. Haaijer-Ruskamp,et al.  Cross-cultural differences in lay attitudes and utilisation of antibiotics in a Belgian and a Dutch city. , 2002, Patient education and counseling.

[12]  S. Salmaso,et al.  Pneumococcal vaccination policy in Europe. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  M. Kaufmann,et al.  Harmonization of Pulsed-Field Gel Electrophoresis Protocols for Epidemiological Typing of Strains of Methicillin-Resistant Staphylococcus aureus: a Single Approach Developed by Consensus in 10 European Laboratories and Its Application for Tracing the Spread of Related Strains , 2003, Journal of Clinical Microbiology.

[14]  N. Woodford,et al.  Multiresistant acinetobacter in the UK: how big a threat? , 2004, The Journal of hospital infection.

[15]  M. Kaufmann,et al.  Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England , 2006, Journal of Clinical Microbiology.

[16]  M. Wilcox,et al.  Does hospital cleanliness correlate with methicillin-resistant Staphylococcus aureus bacteraemia rates? , 2006, The Journal of hospital infection.

[17]  R. Raz,et al.  Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[18]  A. Voss,et al.  Methicillin-ResistantStaphylococcus aureus in Europe , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[19]  A. Widmer,et al.  Transatlantic spread of the USA300 clone of MRSA. , 2005, The New England journal of medicine.

[20]  A. Oliver,et al.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. , 2000, Science.

[21]  Jyoti Gupta,et al.  A population-based study examining the emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 in New York City , 2006, Annals of Clinical Microbiology and Antimicrobials.

[22]  V L Yu,et al.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. , 1991, Annals of internal medicine.

[23]  J. Bartlett Narrative Review: The New Epidemic of Clostridium difficileAssociated Enteric Disease , 2006, Annals of Internal Medicine.

[24]  J. Heritage,et al.  Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. , 1995, The Journal of antimicrobial chemotherapy.

[25]  S. Stone Soil, seed and climate: developing a strategy for prevention and management of infections in UK nursing homes. , 1999, The Journal of hospital infection.

[26]  J. Richardson,et al.  Characterization of a strain of methicillin-resistant Staphylococcus aureus (EMRSA-15) by conventional and molecular methods. , 1993, The Journal of hospital infection.

[27]  S. Cosgrove,et al.  Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacterspp , 2001, Antimicrobial Agents and Chemotherapy.

[28]  J. Hamilton-miller,et al.  Methicillin-resistant Staphylococcus aureus. , 1989, The New England journal of medicine.

[29]  R. Polk Antimicrobial formularies: can they minimize antimicrobial resistance? , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  H. Žemličková,et al.  Emergence of EMRSA-15 clone in hospitals throughout the Czech Republic. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  O. Cars,et al.  A European study on the relationship between antimicrobial use and antimicrobial resistance. , 2002, Emerging infectious diseases.

[32]  N. Woodford,et al.  CTX-M: changing the face of ESBLs in Europe. , 2006, The Journal of antimicrobial chemotherapy.

[33]  J. Quinn,et al.  Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40 , 2006, Antimicrobial Agents and Chemotherapy.

[34]  M. Kaufmann,et al.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. , 2004, The Journal of antimicrobial chemotherapy.

[35]  A. Oliver,et al.  Epidemiology of Extended-Spectrum β-Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period , 2002, Journal of Clinical Microbiology.

[36]  C. Mcnulty,et al.  Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. , 2006, The Journal of antimicrobial chemotherapy.

[37]  E. Bryce,et al.  Focused Microbiological Surveillance and Gram-Negative Beta-Lactamase-Mediated Resistance in an Intensive Care Unit , 1995, Infection Control &#x0026; Hospital Epidemiology.

[38]  Outi Lyytikäinen,et al.  Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002 , 2004, Emerging infectious diseases.

[39]  John M Boyce,et al.  Do Infection Control Measures Work for Methicillin-Resistant Staphylococcus aureus? , 2004, Infection Control &#x0026; Hospital Epidemiology.

[40]  M. Farrington,et al.  Effects on nursing workload of different methicillin-resistant Staphylococcus aureus (MRSA) control strategies. , 2000, The Journal of hospital infection.

[41]  C. Mcnulty,et al.  How should general practitioners investigate suspected urinary tract infection? Variations in laboratory-confirmed bacteriuria in South West England. , 2004, Communicable disease and public health.

[42]  G. Saunders Methicillin resistant Staphylococcus aureus. , 2006, The West Indian medical journal.

[43]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[44]  A. Fraise,et al.  Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. , 2006, The Journal of antimicrobial chemotherapy.

[45]  J. Rodríguez-Baño,et al.  Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  I. Montesinos,et al.  Changes in the epidemiology of meticillin-resistant Staphylococcus aureus associated with the emergence of EMRSA-16 at a university hospital. , 2006, The Journal of hospital infection.

[47]  R. Marples,et al.  A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16) , 1995, The Journal of hospital infection.

[48]  Nnis System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[49]  D. Livermore,et al.  Surveillance of antimicrobial resistance , 1998, BMJ.

[50]  D. Livermore,et al.  Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. , 2001, The Journal of antimicrobial chemotherapy.

[51]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[52]  M. Mulvey,et al.  The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  D. Diekema,et al.  Importance of Control Group Selection for Evaluating Antimicrobial Use as a Risk Factor for Methicillin-Resistant Staphylococcus Aureus Bacteremia , 2005, Infection Control &#x0026; Hospital Epidemiology.

[54]  N. Woodford,et al.  Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. , 2006, The Journal of antimicrobial chemotherapy.

[55]  A. Charlett,et al.  In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. , 2003, International Journal of Antimicrobial Agents.

[56]  D. Felmingham The need for antimicrobial resistance surveillance. , 2002, The Journal of antimicrobial chemotherapy.

[57]  B. Cookson,et al.  Staphylococcus aureus Isolates Carrying Panton-Valentine Leucocidin Genes in England and Wales: Frequency, Characterization, and Association with Clinical Disease , 2005, Journal of Clinical Microbiology.

[58]  A. MacGowan,et al.  Surveillance of antimicrobial resistance , 1998, The Lancet.

[59]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[60]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[61]  J. Patel,et al.  Characterization of a Strain of Community-AssociatedMethicillin-Resistant Staphylococcus aureus WidelyDisseminated in the UnitedStates , 2006, Journal of Clinical Microbiology.

[62]  T. Sandberg,et al.  [How an outbreak of MRSA in Gothenburg was eliminated: by strict hygienic routines and massive control-culture program]. , 2002, Läkartidningen.

[63]  I. Gould,et al.  Fighting MRSA in hospitals: time to restrict the broad use of specific antimicrobial classes? , 2005, The Journal of hospital infection.

[64]  H. Wertheim,et al.  Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. , 2004, The Journal of hospital infection.